We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Opko Health Inc (OPK) Com Stk USD 0.01

Sell:$1.23 Buy:$1.24 Change: $0.005 (0.41%)
NASDAQ:2.18%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.23
Buy:$1.24
Change: $0.005 (0.41%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.23
Buy:$1.24
Change: $0.005 (0.41%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.

Contact details

Address:
4400 Biscayne Blvd.
MIAMI
33137
United States
Telephone:
+1 (305) 5754181
Website:
https://www.opko.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OPK
ISIN:
US68375N1037
Market cap:
$871.24 million
Shares in issue:
696.99 million
Sector:
Health Care Services
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Phillip Frost
    Chairman of the Board, Chief Executive Officer
  • Elias Zerhouni
    President, Vice Chairman of the Board
  • Jane Hsiao
    Vice Chairman of the Board, Chief Technical Officer
  • Adam Logal
    Chief Financial Officer, Senior Vice President, Chief Accounting Officer, Treasurer
  • Charles Bishop
    Chief Executive Officer of OPKO Renal
  • Tony Cruz
    Chief Executive Officer, Transition Therapeutics, Inc
  • Steven Rubin
    Executive Vice President - Administration, Director
  • Gary Nabel
    Chief Innovation Officer, Director

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.